PATENT CLAIM ANALYSIS

Application Number: 15925996
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["544", "281000"]

Abstract:
The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

Claim (Index 86):
The method of  claim 73 , or pharmaceutically acceptable salt thereof, wherein the compound of Formula I is Formula VIII:

Metadata:
- Claim Count in Document: 2.0
- Percentile: 90.0
- Lexical Diversity: 1.35897
- Patent Class: 544.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['11942130', '13033918', '12695636', '11834226', '12813148']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.853132950469886
- 35 USC 102 Novelty (BERT): 0.5686733925085758
- Combined Prediction Score: 0.8246869946737551
- Mean Citation Score: 475.638744
- Max Citation Score: 503.82446
- Similarity Product: 373.9618262603258

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test